393 related articles for article (PubMed ID: 27719640)
1. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
[TBL] [Abstract][Full Text] [Related]
2. Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.
Gowda C; Song C; Kapadia M; Payne JL; Hu T; Ding Y; Dovat S
Adv Biol Regul; 2017 Jan; 63():71-80. PubMed ID: 27666503
[TBL] [Abstract][Full Text] [Related]
3. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.
Song C; Gowda C; Pan X; Ding Y; Tong Y; Tan BH; Wang H; Muthusami S; Ge Z; Sachdev M; Amin SG; Desai D; Gowda K; Gowda R; Robertson GP; Schjerven H; Muschen M; Payne KJ; Dovat S
Blood; 2015 Oct; 126(15):1813-22. PubMed ID: 26219304
[TBL] [Abstract][Full Text] [Related]
4. Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.
Gowda C; Soliman M; Kapadia M; Ding Y; Payne K; Dovat S
Adv Biol Regul; 2017 Aug; 65():16-25. PubMed ID: 28623166
[TBL] [Abstract][Full Text] [Related]
5. Protein signaling and regulation of gene transcription in leukemia: role of the Casein Kinase II-Ikaros axis.
Gowda CS; Song C; Ding Y; Kapadia M; Dovat S
J Investig Med; 2016 Mar; 64(3):735-9. PubMed ID: 26912004
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia.
Klink M; Rahman MA; Song C; Dhanyamraju PK; Ehudin M; Ding Y; Steffens S; Bhadauria P; Iyer S; Aliaga C; Desai D; Huang S; Claxton D; Sharma A; Gowda C
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33807974
[TBL] [Abstract][Full Text] [Related]
7. IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.
Song C; Ge Z; Ding Y; Tan BH; Desai D; Gowda K; Amin S; Gowda R; Robertson GP; Yue F; Huang S; Spiegelman V; Payne JL; Reeves ME; Gurel Z; Iyer S; Dhanyamraju PK; Xiang M; Kawasawa YI; Cury NM; Yunes JA; McGrath M; Schramm J; Su R; Yang Y; Zhao Z; Lyu X; Muschen M; Payne KJ; Gowda C; Dovat S
Blood; 2020 Sep; 136(13):1520-1534. PubMed ID: 32396934
[TBL] [Abstract][Full Text] [Related]
8. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2.
Dovat E; Song C; Hu T; Rahman MA; Dhanyamraju PK; Klink M; Bogush D; Soliman M; Kane S; McGrath M; Ding Y; Desai D; Sharma A; Gowda C
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467550
[TBL] [Abstract][Full Text] [Related]
10. Ikaros, CK2 kinase, and the road to leukemia.
Dovat S; Song C; Payne KJ; Li Z
Mol Cell Biochem; 2011 Oct; 356(1-2):201-7. PubMed ID: 21750978
[TBL] [Abstract][Full Text] [Related]
11. Protein phosphatase 1 (PP1) and Casein Kinase II (CK2) regulate Ikaros-mediated repression of TdT in thymocytes and T-cell leukemia.
Wang H; Song C; Gurel Z; Song N; Ma J; Ouyang H; Lai L; Payne KJ; Dovat S
Pediatr Blood Cancer; 2014 Dec; 61(12):2230-5. PubMed ID: 25214003
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
Wang H; Song C; Ding Y; Pan X; Ge Z; Tan BH; Gowda C; Sachdev M; Muthusami S; Ouyang H; Lai L; Francis OL; Morris CL; Abdel-Azim H; Dorsam G; Xiang M; Payne KJ; Dovat S
J Biol Chem; 2016 Feb; 291(8):4004-18. PubMed ID: 26655717
[TBL] [Abstract][Full Text] [Related]
13. Signaling pathways and regulation of gene expression in hematopoietic cells.
Bogush D; Schramm J; Ding Y; He B; Singh C; Sharma A; Tukaramrao DB; Iyer S; Desai D; Nalesnik G; Hengst J; Bhalodia R; Gowda C; Dovat S
Adv Biol Regul; 2023 May; 88():100942. PubMed ID: 36621151
[TBL] [Abstract][Full Text] [Related]
14. Cellular signaling and epigenetic regulation of gene expression in leukemia.
Gowda C; Song C; Ding Y; Iyer S; Dhanyamraju PK; McGrath M; Bamme Y; Soliman M; Kane S; Payne JL; Dovat S
Adv Biol Regul; 2020 Jan; 75():100665. PubMed ID: 31623972
[TBL] [Abstract][Full Text] [Related]
15. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Prins RC; Burke RT; Tyner JW; Druker BJ; Loriaux MM; Spurgeon SE
Leukemia; 2013 Oct; 27(10):2094-6. PubMed ID: 23900138
[No Abstract] [Full Text] [Related]
16. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition.
Battistutta R
Cell Mol Life Sci; 2009 Jun; 66(11-12):1868-89. PubMed ID: 19387547
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel potent, selective and cell permeable inhibitor of protein kinase CK2 from the NIH/NCI Diversity Set Library.
Guerra B; Hochscherf J; Jensen NB; Issinger OG
Mol Cell Biochem; 2015 Aug; 406(1-2):151-61. PubMed ID: 25963666
[TBL] [Abstract][Full Text] [Related]
19. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.
Perea SE; Baladrón I; Valenzuela C; Perera Y
Semin Oncol; 2018 Jan; 45(1-2):58-67. PubMed ID: 30318085
[TBL] [Abstract][Full Text] [Related]
20. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
